These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 18075282

  • 1. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 2. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T.
    Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
    [Abstract] [Full Text] [Related]

  • 3. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 4. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 5. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 6. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 7. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome.
    Aubert H, Frère C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC.
    J Thromb Haemost; 2003 Apr; 1(4):791-7. PubMed ID: 12871417
    [Abstract] [Full Text] [Related]

  • 8. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 9. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 06; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct 06; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 11. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ, Verhamme P, Gils A.
    Thromb Res; 2014 Nov 06; 134(5):1097-102. PubMed ID: 25193405
    [Abstract] [Full Text] [Related]

  • 12. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 06; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 13. Fibrinolysis parameters in Sudanese women with severe preeclampsia.
    Elzein HO, Muddathir AR, Rida M, Rayis DA, Elhassan EM, Adam I.
    Hypertens Pregnancy; 2016 Nov 06; 35(4):559-564. PubMed ID: 27598010
    [Abstract] [Full Text] [Related]

  • 14. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 15. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep 08; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 16. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B, Demir T, Comlekci A, Yener S, Ozcan MA, Karaoglu O, Yuksel F, Secil M, Yesil S.
    Med Princ Pract; 2011 Sep 08; 20(1):23-8. PubMed ID: 21160209
    [Abstract] [Full Text] [Related]

  • 17. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep 08; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 08; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 19. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Apr 08; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 20. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
    Güldaş M, Altinkaya SÖ, Nergiz S, Demircan-Sezer S, Yüksel H.
    Gynecol Endocrinol; 2015 Jul 08; 31(7):536-9. PubMed ID: 26220768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.